Hemochromatosis and bipolar disorder

General Hospital Psychiatry

Volumn 34, Issue 4, 2012, Pages 433-435

  Anderson, George ^a  

^a CRC   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IRON; KYNURENINE; MELATONIN; MELATONIN RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; QUINOLINIC ACID; SEROTONIN; TRYPTOPHAN;

BIOSYNTHESIS; BIPOLAR DISORDER; BRAIN REGION; CIRCADIAN RHYTHM SLEEP DISORDER; DISEASE ACTIVITY; DISEASE ASSOCIATION; EXCITOTOXICITY; FENTON REACTION; GENE; GENE FUNCTION; GENETIC SUSCEPTIBILITY; HEMOCHROMATOSIS; HUMAN; LETTER; MELATONIN RECEPTOR GENE; MICROGLIA; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; PROTEIN FUNCTION; PUBLICATION; REGULATORY MECHANISM; SCHIZOPHRENIA;

BIPOLAR DISORDER; HEMOCHROMATOSIS; HUMANS; MALE;

EID: 84862753282     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2012.04.005     Document Type: Letter

References (7)

1. Serata D., Del Casale A., Rapinesi C., Mancinelli I., Pompili P., Kotzalidis G.D., et al. Hemochromatosis-induced bipolar disorder: a case report. Gen Hosp Psychiatry 2012, 34:101.e1-101.e3.
2. Stachowski E.K., Schwarcz R. Regulation of quinolinic acid neosynthesis in mouse, rat and human brain by iron and iron chelators in vitro. J Neural Transm 2011, 10.1007/s00702-011-0694-6.
3. Steiner J., Walter M., Gos T., Guillemin G.J., Bernstein H.G., Sarnyai Z., et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: Evidence for an immune-modulated glutamatergic neurotransmission?. J Neuroinflammation 2011, 8:94.
4. Kell D.B. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol 2010, 84:825-889.
5. Park H.J., Park J.K., Kim S.K., Cho A.R., Kim J.W., Yim S.V., et al. Association of polymorphism in the promoter of the melatonin receptor 1A gene with schizophrenia and with insomnia symptoms in schizophrenia patients. J Mol Neurosci 2011, 45(2):304-308.
6. Shamir E., Barak Y., Shalman I., Laudon M., Zisapel N., Tarrasch R., et al. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry 2001, 58(11):1049-1052.
7. Srinivasan V., Cardinali D.P., Pandi-Perumal S.R., Brown G.M. Melatonin agonists for treatment of sleep and depressive disorders. J Exp Integr Med 2011, 1(3):149-158.